Cargando…
Assessing the risk of adalimumab use for hidradenitis suppurativa during the COVID-19 pandemic
Autores principales: | Kearns, Donovan G., Chat, Vipawee S., Uppal, Shelley, Wu, Jashin J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
by the American Academy of Dermatology, Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7385551/ https://www.ncbi.nlm.nih.gov/pubmed/32735966 http://dx.doi.org/10.1016/j.jaad.2020.07.086 |
Ejemplares similares
-
Assessing the risk of dupilumab use for atopic dermatitis during the COVID-19 pandemic
por: Kearns, Donovan G., et al.
Publicado: (2020) -
Reply to Letter to the Editor Regarding: “Applying to dermatology residency during the COVID-19 pandemic”
por: Kearns, Donovan G., et al.
Publicado: (2021) -
Adalimumab for treatment of hidradenitis suppurativa during the COVID-19 pandemic: Safety considerations
por: Blaszczak, Alecia, et al.
Publicado: (2020) -
Hidradenitis suppurativa: The importance of virtual outpatient care during COVID-19 pandemic
por: Shah, Monica, et al.
Publicado: (2020) -
Exploring the risk of severe COVID-19 infection in patients with hidradenitis suppurativa
por: Seltzer, Janyla A., et al.
Publicado: (2020)